A comparison of reweighting estimators of average treatment effects in real world populations.

ABSTRACT: Regulatory agencies typically evaluate the efficacy and safety of new interventions and grant commercial approval based on randomized controlled trials (RCTs). Other major healthcare stakeholders, such as insurance companies and health technology assessment agencies, while basing initial access and reimbursement decisions on RCT results, are also keenly interested in whether results observed in idealized trial settings will translate into comparable outcomes in real world settings-that is, into so-called "real world" effectiveness. Unfortunately, evidence of real world effectiveness for new interventions is not available at the time of initial approval. To bridge this gap, statistical methods are available to extend the estimated treatment effect observed in a RCT to a target population. T

SUBMITTER: Lin CY 

PROVIDER: S-EPMC8359356 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature